Значения термина rectal toxicity на английском

Conclusions: Supplemental EBRT may lower the threshold for rectal toxicity after prostate brachytherapy.

Multivariate analyses were performed to identify predictors of acute and late rectal toxicity.

IMRT combined with IGRT markedly decreases acute and late rectal toxicity.

Conclusions: Dose escalation and moderate hypofractionation increase late rectal toxicity.

Analysis of variance was used to examine the association between rectal toxicity and rectal dose.

Severe late rectal toxicity after prostate brachytherapy was rare.

No independent factor was identified for acute rectal toxicity.

No patients developed acute Grade 3 rectal toxicity.

Purpose: To evaluate the urinary and rectal toxicity secondary to 3D conformal radiotherapy for prostate cancer.

Our nomogram predicts the 3-year rectal toxicity risk by integrating total dose, fraction dose, and RT technique.

To determine whether rectal dose-volume histogram as well as patient and treatment factors were associated with rectal toxicity.

The actuarial late Grade 3 rectal toxicity rate at 5 years was 3%.

The multivariate Cox proportional hazards model selected V75 as the only value of VDose significantly associated with late rectal toxicity.

Conclusions: There is no evidence from these data that intermediate doses influence the risk of Grade ≥ 2 late rectal toxicity.

Objective: To describe the acute and late rectal toxicity in 1006 prostate brachytherapy patients implanted 1998-2003.

In prostate cancer, intensity-modulated radiotherapy has resulted in reduced rectal toxicity and has permitted tumor dose escalation to previously unattainable levels.